第一单位：
Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
作者：
Hana M,El Sahly [1]
;
Lindsey R,Baden [2]
;
Brandon,Essink [3]
;
David,Montefiori [4]
;
Adrian,McDermont [5]
;
Richard,Rupp [6]
;
Michael,Lewis [7]
;
Shobha,Swaminathan [8]
;
Carl,Griffin [9]
;
Veronica,Fragoso [10]
;
Vicki E,Miller [11]
;
Bethany,Girard [12]
;
Yamuna D,Paila [12]
;
Weiping,Deng [12]
;
Joanne E,Tomassini [12]
;
Robert,Paris [12]
;
Florian,Schödel [12]
;
Rituparna,Das [12]
;
Allison,August [12]
;
Brett,Leav [12]
;
Jacqueline M,Miller [12]
;
Honghong,Zhou [12]
;
Rolando,Pajon [12]
;
Coronavirus Efficacy (COVE) Study Group
作者单位：
Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
[1]
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
[2]
Meridian Clinical Research, Omaha, Nebraska, USA.
[3]
Immune Assay Team, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
[4]
Vaccine Research Center, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
[5]
Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA.
[6]
Department of Pathology, Veterans Affairs Greater Los Angeles Healthcare, Los Angeles, California, USA.
[7]
Department of Medicine, Rutgers, New Jersey Medical School, Newark, New Jersey, USA.
[8]
Lynn Health Science Institute, Oklahoma City, Oklahoma, USA.
[9]
Texas Center for Drug Development, DM Clinical Research, Houston, Texas, USA.
[10]
Texas Center for Drug Development, DM Clinical Research, Tomball, Texas, USA.
[11]
Infectious Disease Development, Moderna, Inc., Cambridge, Massachusetts, USA.
[12]
DOI
10.1093/infdis/jiac188
PMID
35535503
发布时间
2024-09-23
换一批
换一批
